Argo Biopharma's positive Phase II update for siRNA therapeutic BW-20805 highlights advancing RNAi approach for hereditary angioedema ahead of symposium presentation
Executive summary: Argo Biopharma released updated positive Phase II data for its siRNA therapeutic BW-20805 for hereditary angioedema and scheduled an oral presentation at the Bradykinin Symposium 2026 on September 4, 2026. Positive Phase II results suggest BW-20805 could become a novel RNAi-based treatment for HAE, addressing an unmet medical need and potentially reshaping the therapeutic landscape.
Who is involved: Argo Biopharma (clinical-stage siRNA therapeutics company), the Phase II investigative team, and the organizers of the Bradykinin Symposium 2026.
Likely next: Presentation of the updated Phase II data at the Bradykinin Symposium 2026, followed by potential disclosure of full results and planning for subsequent clinical steps.
Argo Biopharma announced updated positive Phase II results for its siRNA candidate BW-20805 targeting hereditary angioedema (HAE) and will present the data at the Bradykinin Symposium 2026. The announcement indicates that the therapy met efficacy and safety endpoints in the Phase II study, supporting further clinical development. No contradictory data or safety concerns were reported in the release.
Timeline
- — Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026 (PR Newswire)
- — Haemonetics (HAE) Q1 2027 Earnings Call Transcript (Yahoo Finance)
Analysis — what this means
Likely next events
- Argo Biopharma to present updated Phase II BW-20805 data at Bradykinin Symposium 2026 on September 4, 2026
Sectors affected
- Biotechnology
- RNAi therapeutics
- Hereditary angioedema treatment
Historical parallels
- Haemonetics (HAE) Q1 2027 earnings call (August 13, 2026) discussed HAE market trends